Stanford researchers test drug to fight depression faster in elderly

October 16, 2002

STANFORD, Calif. - Elderly people who suffer from depression can take the edge off faster by using a drug called mirtazapine, which appears to work more quickly compared to rival drugs. These results come from a study by researchers at Stanford University Medical Center who compared two drugs in an eight-week trial. Although both drugs treated the depression, mirtazapine began working sooner and eased the patient's anxiety - a common effect of depression in elderly people.

"There's a sense that we need something else for elderly patients and here is an alternative that is well tolerated," said Alan Schatzberg, MD, the Kenneth T. Norris, Jr. Professor of Psychiatry and Behavioral Sciences. "It gives doctors an alternative."

Anti-depression drugs come in two common varieties. Selective serotonin reuptake inhibitors (SSRIs), such as the popular Zoloft and Prozac, cause the brain chemical serotonin to linger in the gaps between neurons. These drugs are extremely effective but can interact with other drugs such as beta-blockers, which many elderly people take to quell heart problems.

The alternative to SSRIs - tricyclic antidepressants (TCAs) - can have side effects that make them less appealing. However, mirtazapine, a non-tricyclic that works similarly to TCA's, has few side effects or drug interactions. "Mirtazapine has TCA-like properties without the side effects," Schatzberg said. "A lot of people use it where they might have used a TCA, particularly in the elderly." Mirtazapine enhances the effects of serotonin and other brain chemicals and also acts as a mild sedative.

Schatzberg tested mirtazapine's effectiveness against paroxetine (sold under the name Paxil), a popular SSRI. In his trial, 255 depressed people 65 or older were randomly divided into groups taking either mirtazapine or paroxetine. Psychiatrists analyzed the patients' depression throughout an eight-week test period.

Although the drugs were equally effective by the end of the eight-week period, depression in patients on mirtazapine had eased significantly by day 14 compared with people taking paroxetine. Those patients also had less anxiety and an easier time sleeping. In addition, those who took mirtazapine had fewer side effects such as nausea, tremors or flatulence - side effects that caused 26 percent of those taking paroxetine to discontinue the trial compared with 15 percent of those on mirtazapine. During an extended eight-week phase after the initial trial, the two drugs remained equally effective.

Schatzberg said mirtazapine is also effective more quickly than SSRIs in younger people; however younger people are less likely to stay on the drug because it can cause some weight gain and grogginess. "Weight gain is a problem for younger patients," Schatzberg said. "There's less initiative to use the drug in these people."

These side effects that drive younger patients away can be a boon to the elderly who are less concerned about their weight but who suffer from anxiety and insomnia. "Depressed people who are older often have agitation," Schatzberg said. "Mirtazapine calmed these patients and helped them sleep, especially early on."

Schatzberg said that many doctors already use mirtazapine to treat depression in their elderly patients in order to avoid the drug interactions that are common with SSRIs. "But it certainly hasn't saturated the market in the elderly," he noted.
-end-
Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at http://mednews.stanford.edu.

Stanford University Medical Center

Related Depression Articles from Brightsurf:

Children with social anxiety, maternal history of depression more likely to develop depression
Although researchers have known for decades that depression runs in families, new research from Binghamton University, State University of New York, suggests that children suffering from social anxiety may be at particular risk for depression in the future.

Depression and use of marijuana among US adults
This study examined the association of depression with cannabis use among US adults and the trends for this association from 2005 to 2016.

Maternal depression increases odds of depression in offspring, study shows
Depression in mothers during and after pregnancy increased the odds of depression in offspring during adolescence and adulthood by 70%.

Targeting depression: Researchers ID symptom-specific targets for treatment of depression
For the first time, physician-scientists at Beth Israel Deaconess Medical Center have identified two clusters of depressive symptoms that responded to two distinct neuroanatomical treatment targets in patients who underwent transcranial magnetic brain stimulation (TMS) for treatment of depression.

A biological mechanism for depression
Researchers report that in depressed individuals there are increased amounts of an unmodified structural protein, called tubulin, in lipid rafts compared with non-depressed individuals.

Depression in adults who are overweight or obese
In an analysis of primary care records of 519,513 UK adults who were overweight or obese between 2000-2016 and followed up until 2019, the incidence of new cases of depression was 92 per 10,000 people per year.

Why stress doesn't always cause depression
Rats susceptible to anhedonia, a core symptom of depression, possess more serotonin neurons after being exposed to chronic stress, but the effect can be reversed through amygdala activation, according to new research in JNeurosci.

Which comes first: Smartphone dependency or depression?
New research suggests a person's reliance on his or her smartphone predicts greater loneliness and depressive symptoms, as opposed to the other way around.

Depression breakthrough
Major depressive disorder -- referred to colloquially as the 'black dog' -- has been identified as a genetic cause for 20 distinct diseases, providing vital information to help detect and manage high rates of physical illnesses in people diagnosed with depression.

CPAP provides relief from depression
Researchers have found that continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA) can improve depression symptoms in patients suffering from cardiovascular diseases.

Read More: Depression News and Depression Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.